Breaking News
Investing Pro 0
💎 Reveal Undervalued Stocks Hiding in Any Market Get Started

Tilray Simply Needs To Do Better

By Vince MartinStock MarketsSep 08, 2022 01:31PM ET
www.investing.com/analysis/tilray-simply-needs-to-do-better-200629569
Tilray Simply Needs To Do Better
By Vince Martin   |  Sep 08, 2022 01:31PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
TLRY
0.38%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
CGC
-0.52%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
HEXO
+4.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
TCNNF
-0.52%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
  • From a broad perspective, the story surrounding TLRY stock is delayed, not broken
  • But subpar execution has been as big a problem as slow regulators
  • Long term, the stock can still work out, but at the current valuation it’s difficult to be terribly optimistic

There’s an argument to be made that Tilray (NASDAQ:TLRY) still is on track, if moving slower than hoped. Over the past few years, Tilray’s strategy has been to build its footprint out across geographies and end markets in advance of cannabis legalization in major markets.

Certainly, that strategy has done little for Tilray stock, which has dropped 76% over the past year and is threatening March 2020 lows. But bulls might argue that the weakness in TLRY is being driven by a sector sell-off and/or impatient investors, not anything Tilray itself is doing wrong.

There perhaps is some truth to that argument — but not enough. Tilray has not performed well of late, a problem that has amplified external pressure on the stock.

The good news for TLRY is that the company has time to improve. The bad news is that, even down by three-quarters, some degree of improvement is priced in.

The Long-Term Case For Tilray Stock

The broad argument for Tilray stock is that no company is better positioned for global cannabis legalization.

In Canada, immediately after the merger of Tilray and Aphria, the combined company had leading market share. Tilray held about 20% of the market, nicely ahead of second-place Canopy Growth (NASDAQ:CGC).

In the U.S., Aphria’s acquisition of Sweetwater Brewing provided the opportunity to manufacture cannabis-infused beverages. Importantly, it also established access to distribution, allowing Tilray to quickly ramp sales the instant federal cannabis legalization arrived. The Manitoba Harvest brand has moved the company into hemp-based foods as well.

And in Europe, via CC Pharma, Tilray owns distribution in the medical cannabis channel. It has large manufacturing facilities in both Germany and Portugal that serve medical customers. Both facilities have the capacity to serve adult-use customers on the continent when legalization of recreational marijuana arrives.

In a world where cannabis is legalized, these constituent parts all fit nicely together. Cannabis produced by Tilray can be distributed either through owned channels or through relationships built by Sweetwater and Manitoba Harvest, in particular. Those businesses also provide the opportunity to create myriad cannabis-based products, whether edibles or beverages.

In short, once cannabis legalization truly arrives, Tilray will have its hands in almost every aspect of the global business.

What’s Gone Wrong?

One core problem for Tilray — and its Canadian rivals — is that global cannabis legalization hasn’t arrived.

After elections in 2020, observers — including Tilray chief executive officer Irwin Simon — predicted the U.S. was on a path to removing the federal prohibition on the product. But little progress has been made. In Europe, Simon has pinned his hopes on Germany, where a draft bill is expected later this year.

The positive interpretation of TLRY here would be that the company has set itself up for a world that doesn’t yet exist — through no part of its own. Legalization has moved slower than most believed it would. And because of that, Tilray owns production and distribution assets that are being under-utilized.

Eventually, that will change. Tilray will be able to take advantage of its positioning. In the meantime, the company remains reasonably profitable. In fiscal 2023, the company expects $70 million to $80 million in adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). More synergies from the partnership with Hexo (NASDAQ:HEXO)) should arrive in FY24.

All told, the bull case is that Tilray’s opportunity hasn’t disappeared. It’s simply been delayed. As long as the company keeps muddling through without markets like Germany and the U.S., it should prosper once those markets finally open up.

Execution Needs To Improve

It’s a tempting bull case. After the long plunge, TLRY stock isn’t that expensive relative to profits or revenue. Shares trade at about 3x this year’s sales, and under 30x EBITDA. Neither multiple is “cheap,” necessarily, but with long-term growth on the horizon (again, at some point) both seem acceptable.

The catch is that Tilray’s execution simply has to improve. The focus on potential markets can miss the fact that Tilray is underperforming in existing markets.

In Canada, Tilray continues to hemorrhage market share. In Q4, according to the company itself, Tilray had barely 8% share, less than half the figure seen just two years ago. Performance in Israel has disappointed due to an oversupplied market. Even Sweetwater appears to have posted soft results in recent quarters.

It’s possible that the problems facing Tilray aren’t company-specific. But that’s not good news, either. The long-term bear case for cannabis companies has been that the product is not differentiated. That, in turn, leads to “race to the bottom” pricing, low profit margins and volatile market share. That combination is precisely what Tilray faces in its home market of Canada at the moment.

It’s the environment in Canada that raises perhaps the most concern about Tilray stock. If Tilray can’t win at home, at a time when publicly traded producers are struggling with debt and after the industry’s largest-ever merger, is it necessarily going to win in the U.S.? Or, will the established MSOs (multi-state operators) like Trulieve (OTC:TCNNF)) and Curaleaf Holdings (OTC:CURLF) dominate on their own turf?

Right now, investors are picking the MSOs, whose market caps exceed those of their larger rivals. TLRY stock likely can’t find consistent upside until that changes.

Disclaimer: As of this writing, Vince Martin has no positions in any securities mentioned.

Tilray Simply Needs To Do Better
 

Related Articles

Tilray Simply Needs To Do Better

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (4)
Osman Saglam
LACS Sep 09, 2022 7:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
comparing israel to germany ,,, get real dude , israel is a tiny market ,,, why dony u mention 20 percent leading markrtshare in germany that is immiinent to legalize , ethics my friend !!!!
Osman Saglam
LACS Sep 09, 2022 7:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
just another one of those articles supporting shorters , also 8 percent market share in Canada is a LIE,
Joseph Obrzut
jzut Sep 08, 2022 4:47PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Are people still interested/care about marijuana stocks????
Luuk Bernard
Luuk Bernard Sep 08, 2022 1:48PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dilution again and again
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email